Torna all'elenco degli studi

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

CODICE STUDIO

NCT04643002

TIPOLOGIA

Ricaduti

NOME SPONSOR

Sanofi

DESCRIZIONE

Trattamento

Active Comparator: Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 1)

  • Isatuximab dose, intravenous (IV) weekly (QW) x 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).
  • Pomalidomide dose os (PO) daily Day 1 to Day 21.
  • Dexamethasone dose PO QW.

 

Leggi tutto

FARMACI UTILIZZATI

Isatuximab, Belantamab Mafodotin, Pomalidomide, Desametasone